Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Chemistry and Immunoassay Analyzers for Mid- and High-Volume Laboratories, 2024

[one_third]

[/one_third]

[one_third]

[/one_third]

[one_third_last]

[/one_third_last]

[wpdatatable id=105]

[one_third]

DOWNLOAD PDF

[/one_third]
[two_third_last]

Lab, vendor views on instruments, assays, and data

Instruments, assays, patient flow, and IT were some of what laboratory directors and IVD company representatives spoke of when CAP TODAY publisher Bob McGonnagle convened the group online on May 3. Here’s what they said about what instruments and assays are deployed where and the considerations that come into play in large health systems.

CAP TODAY’s guide to chemistry and immunoassay analyzers for mid- and high-volume laboratories begins here. The guide to analyzers for use at the point of care and in low-volume labs, in the June issue, is at https://bit.ly/CT_0624-PG.

During last year’s roundtable on chemistry and immunoassay systems, there was an emphasis on labs needing to be agile and adaptive and to know they might be a hub or a spoke in this environment of consolidation. Being nimble and flexible is important to being able to grow and scale, particularly being able to deploy instruments as conditions dictate.

Stephens

Ryan Stephens, talk to us about the aging population, which has deep significance for the workforce and the patient population you’ll be testing, and consolidation. How do you see it coming?

Ryan Stephens, group marketing manager, automation and core lab digital solutions, Roche: One challenge with an aging population is access. How do you ensure access to laboratory medicine for this population, especially in rural areas where the draw station or closest lab might be a couple of hours away and they might not have reliable transportation. How do we work with new services that are coming out with at-home testing or sampling and integrate it into our testing practice? How do we provide access as staffing becomes more difficult? As the population ages, monitoring them with laboratory diagnostics will be increasingly important so you can get them the right therapies and treatments and help improve their health, which will ultimately reduce the overall cost of health care in the U.S.

Continue reading …
[/two_third_last]